Promedior
 

About Promedior

Leadership in Fibrosis

Scientific Background
Promedior's New Therapeutic Paradigm
 
UNIQUE BENEFITS OF PTX-2
R&D PLATFORM
PRECLINICAL EFFICACY MODELS
Potential of Pentraxin Therapeutics
Publications
Select Links

Pipeline

News & Events

Careers

Contact Us

Home

LEADERSHIP IN FIBROSIS: Publications

PTX-2/SAP in Fibrosis

Santhiago MR, et al. (2011) Monocyte development inhibitor PRM-151 decreases corneal
myofibroblast generation in rabbits
. Experimental Eye Research Sep 14.

Murray, et al. (2010) TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol. Oct 28. [Epub ahead of print]

Moreira, et al. (2010) Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. Epub Jul 29

Murray LA, et al. (2010) Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis & Tissue Repair. 3:11.

Duffield JS and Lupher ML Jr. (2010) PRM-151 (recombinant human serum amyloid P/Pentraxin 2) for the treatment of fibrosis. Drug News & Perspectives. 23(5).

Murray LA, et al. (2010) Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. Mar 12;5(3):e9683.

Castaño AP, Lin SL et al. (2009). Serum amyoid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Science Trans Med Nov 4 (epub).

Haudek SB, Trial J et al. (2008) Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci U S A. Jul 22;105(29):10179-84.

Shao DD, Suresh R et al. (2008). Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. Jun;83(6):1323-33.

Naik-Mathuria B, Pilling D et al. (2008). Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. Mar-Apr;16(2):266-73.

Pilling D, Roife D et al. (2007). Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007 Sep 15;179(6):4035-44.

Pilling, D., N. M. Tucker, et al. (2006). Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 79(6): 1242-51.

Haudek SB, Xia Y et al. (2006). Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A. Nov 28;103(48):18284-9.

Pilling, D., C. D. Buckley, et al. (2003). Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 171(10): 5537-46.

[ back to top ]

Monocyte-derived cells in Fibrosis

Mathai SK, et al. (2010) Circulating Monocytes from Systemic Sclerosis Patients with Interstitial Lung Disease Show an Enhanced Profibrotic Phenotype. Lab Invest. Jun;90(6):812-23. Epub 2010 Apr 19.

Moeller A, et al. (2009) Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(7): 588-94.

Lin SL, Castaño AP et al. (2009). Bone Marrow Ly6Chigh Monocytes Are Selectively Recruited to Injured Kidney and Differentiate into Functionally Distinct Populations. J Immunol. Oct 28 (epub).

Pilling D, Fan T et al. (2009) Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One. Oct 16;4(10):e7475.

Mehrad B et al. (2007) Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. Feb 2;353(1):104-8. Epub 2006 Dec 11

Wang, J. F., H. Jiao, et al. (2007). Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 15(1): 113-21.

Cowper, S. E. and P. J. Boyer (2006). Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8(2): 151-7.

Gaedeke, J., H. H. Neumayer, et al. (2006). Pharmacological management of renal fibrotic disease. Expert Opin Pharmacother 7(4): 377-86.

Kisseleva, T., H. Uchinami, et al. (2006). Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45(3): 429-38.

Lama, V. N. and S. H. Phan (2006). The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 3(4): 373-6.

Lupher, M.L. and W.M. Galatin (2006). Regulation of Fibrosis by the Immune System. Adv Immunol 89: 245-88.

Quan, T. E., S. E. Cowper, et al. (2006). The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8(2): 145-50.

Varcoe, R. L., M. Mikhail, et al. (2006). The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 4(5): 1125-33.

Garlanda, C., B. Bottazzi, et al. (2005). Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-66.

Mori, L., A. Bellini, et al. (2005). Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 304(1): 81-90.

Canbay, A., S. Friedman, et al. (2004). Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39(2): 273-8.

Garantziotis, S., M. P. Steele, et al. (2004). Pulmonary fibrosis: thinking outside of the lung. J Clin Invest 114(3): 319-21.

Gregory, C. D. and A. Devitt (2004). The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113(1): 1-14.

Phillips, R. J., M. D. Burdick, et al. (2004). Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114(3): 438-46.

Gordon, S. (2003). Alternative activation of macrophages. Nat Rev Immunol 3(1): 23-35.

Chesney, J., C. Metz, et al. (1998). Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J J Immunol 160(1): 419-25.

[ back to top ]

General Fibrosis Reviews

Gomer RH and Lupher ML Jr. (2010) Investigational approaches to therapies for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. Jun;19(6):737-45.

Lupher, M.L. and W.M. Galatin (2006). Regulation of Fibrosis by the Immune System. Adv Immunol 89: 245-88.

Bataller, R. and D. A. Brenner (2005). Liver fibrosis. J Clin Invest 115(2): 209-18.

Friedman, S. L. (2003). Liver fibrosis -- from bench to bedside. J Hepatol 38 Suppl 1: S38-53.

Tomasek, J. J., G. Gabbiani, et al. (2002). Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol3(5): 349-63.

[ back to top ]

 

Fibrosis is the common pathway in virtually all forms of chronic organ failure, including kidney, liver, lung and heart failure. Fibrotic organ failure affects more than 20 million people in the US alone.

 
   
 

design by Digizyme